global pharma industry
Post on 02-Jun-2018
228 Views
Preview:
TRANSCRIPT
-
8/11/2019 Global pharma industry
1/15
-
8/11/2019 Global pharma industry
2/15
Internal
Environment
Five forces
Model
External
Environment
PESTEL
-
8/11/2019 Global pharma industry
3/15
Highly fragmented industry in 80s. Mergers ledto concentration of jobs in select countries.
More control thereby exercised by Governments.
Easy Targets To control rising healthcare costs
when medicines amount to 15% of healthcareexpenditure.
Multi country pricing due to Governmentregulations.
Patent on drugs India patents the process whileUS and EU patent the drug
-
8/11/2019 Global pharma industry
4/15
emand side
Doctors tend to favor branded drugs which are highmargin.
Globalization has made it possible for big companies to
mass market the drugs.Supply side
Global supply is fragmented. Pfizer has largest marketshare of 11%.
Regional players and the generic drugs which arerelatively cheaper are popular in developing world.
Need for blockbuster products as R&D investments donot justify the number of new drugs.
-
8/11/2019 Global pharma industry
5/15
Advancement in medicine has raised the lifeexpectancy to 75 and aged populationincreases the consumption. This adds strainon insurance companies and governments.
Socially aware, well informed and demandingconsumers.
Increasing aging population offered a rangeof opportunities
Increase in life style diseases and hence morepharma companies shift their focus to alucrative option
-
8/11/2019 Global pharma industry
6/15
System controlling clinical trials andregulatory approvals underwentmodernisation, leaving many domesticcompanies ill equipped
More technology, consumers became moreaware, resulting in increased demand andalso increased awareness aboutinternational price disparity
E-detailing used by sales force of pharmacompanies as a measure to cost cutting andtime saving
-
8/11/2019 Global pharma industry
7/15
There is a growing environmental agenda and the key stakeholders are now becoming more aware of the need forbusinesses to be more proactive in this field.Pharma companies need to see how their business and
marketing plans link in with the environmental issues.There is also an opportunity to incorporate it within theirCorporate Social Responsibility programmes. Marketing andnew product development should identify eco opportunitiesto promote as well. Human Genome and genetics are new
ways to discover drugs
-
8/11/2019 Global pharma industry
8/15
Varied patent laws in different countries. Many best selling drugs are replicated as generic medicine
in developing countries with full government backing. Clinical trials have become more rigorous thereby testing
more than 20,000 people in the complete run of 10-14years.
The industry benefitted in the 1960s due to newdiscoveries with permanent patent protection.
Thalidomide tragedy led to increase in the regulatorycontrol on clinical trials.
Fixed period on patent protection was introduced
typically 20 years. Due to enormous risks and large investment involved,firms started to compete fiercely in order to establish andretain the intellectual property rights.
-
8/11/2019 Global pharma industry
9/15
Generics legislation provided an incentive for innovation and arace to the market. Government agencies took long time to examine the data due to
rigorous regulatory scrutiny. To bring regulatory process harmonization, EMEA was
established to enable more rapid approvals across Europe
through centralized procedure. EU countries augmented voluntary codes of conduct with formalregulation after 2003.
Regulatory changes in 1997 permitted the pharmaceuticalcompanies to market directly to US customers fuelling rapidsales growth.
Japans regulatory system underwent a modernisation programwhich at the end resulted in low pharmaceutical growth of 1% in2002.
Expensive intellectual property rights led the companies to formresearch alliances.
-
8/11/2019 Global pharma industry
10/15
-
8/11/2019 Global pharma industry
11/15
The industry has already high entry barrierswhich are increasing.
Need for global return on costly R&D favorslarge firms only
Emphasis on high-priced niche drugs for highunmet need diseases likely to support marketentry by bio techs.
-
8/11/2019 Global pharma industry
12/15
-
8/11/2019 Global pharma industry
13/15
Here the influencers are doctors, hospital,government and not the end consumers, so endconsumers do not have much bargaining power ,brand identity exists but in the hands of theinfluencer
The doctors are price insensitive but susceptible tosales Governments and managed health organizations
imposing systems to control prices/reimbursementand demand
Rising patient expectations and growth of managedcare continues deteriorating the profitability of bigpharmaceuticals regardless of the outcome ofregulation
Substitutes available and so bargaining power is high
-
8/11/2019 Global pharma industry
14/15
Threat of substitutes is high Generics appear at a cheaper rate than the
branded drugs
Consumer suspicion of drugs leads toincreasing use of alternative remedies
Functional foods preferred as safer alternativeto drugs
Diversification into generics protects volumeshare (but not the profit) of bigpharmaceutical companies
-
8/11/2019 Global pharma industry
15/15
Profitable, cash-rich industry but marginsdeclining.
Mergers and acquisitions are expected tocontinue as they could lead to economies ofscale, global sales and marketing and moreefficient R&D efforts.
Intense rivalry within product classes.
top related